Six compounds had a high common sensitivity rate (about 50%), low complete cross-resistance rate (3.4~10.7%), and low partial cross-resistance rate to Eco, Pae, and other Ebc, which indicated that the therapeutic effects of these six compounds on the infections of Eco, Pae, and other Ebc could be replaced by each other. Here, CILK1 is linked to infection.